1700632908
[13] Recker R, Ensrud K, Diem S, et al. Normal bone histomorphometry and 3D microarchitecture after 10 years alendronate treatment of postmenopausal women. J Bone Miner Res, 2004, 19
:45.
1700632909
1700632910
[14] Harris ST, Watts NB, Genant HK, et al. For the Vertebral Efficacy with Risedronate Therapy（VERT）Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA, 1999, 282
:1344-1352.
1700632911
1700632912
[15] Reginster J, Minne HW, Sorensen OH, et al. For the Vertebral Efficacy with Risedronate Therapy（VERT）Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int, 2000, 11
:83-91.
1700632913
1700632914
[16] Reginster J, Minne HW, Sorensen OH, et al. For the Vertebral Efficacy with Risedronate Therapy（VERT）Study Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int, 2000, 11
:83-91.
1700632915
1700632916
[17] Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int. 2002, 71
:103-111.
1700632917
1700632918
[18] Greenblatt D. Treatment of postmenopausal osteoporosis. Pharmacotherapy. 2005, 25
:574-584.
1700632919
1700632920
[19] Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: The emerging role of intermittent therapy. Clin Ther, 2005, 27
:361-376.
1700632921
1700632922
[20] Barrett J, Worth E, Bauss F, Epstein S. Ibandronate: A clinical pharmacological and pharmacokinetic update. J Clin Pharmacol, 2004, 44
:951-965.
1700632923
1700632924
[21] Chestnut CH III, Skag A, Christiansen C, et al. For the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe（BONE). EFFects of oral ibandronate administered daily or intermittently on Fracture risk in postmenopausal osteoporosis. J Bone Miner Res, 2004, 19
:1241-1249.
1700632925
1700632926
[22] Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-Year results from the MOBILE study. J Bone Miner Res, 2005, 20
:1315-1322.
1700632927
1700632928
[23] Recker R, Stakkestad JA, Chesnut CH III，et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal postmenopausal osteoporosis. Bone, 2004, 34
:890-899.
1700632929
1700632930
[24] Adami S, Felsenberg D, Christiansen C, et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone, 2004, 34
:881-889.
1700632931
1700632932
[25] Solomon Epstein, MD. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Solomon Epstein. clinical therapeutics, 2006, 28
:151-173
1700632933
1700632934
[26] Rosen CJ, Hochberg MC, Bonnick SL, et al. For the fosamax actonel comparison trial investigators. treatment with once-weekly Mendronate 70mg compared with once-weekly risedronate 35mg in women with postmenopausal osteoporosis: A randomized doubleblind study. J Bone Miner Res, 2005, 20
:141-151.
1700632935
1700632936
[27] Eastell R, Delmas PD. How to interpret surrogate markers of efficacy in osteoporosis. J Bone Miner Res, 2005, 20
:1261-1262.
1700632937
1700632938
[28] Guyatt GH, Cranney A, Griffith L, et al. Summary of meta-anatyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinol Metab Clin Nortk Am, 2002, 31
:659-679.
1700632939
1700632940
[29] Lindsay R, Magowan S, Miller P, et al. Treatment-related changes in BMD are not associated with the occurrence of a fragility fracture while on risedronate therapy. Poster presented at: 27th Annual Meeting of the American Society for Bone and Mineral Research, 2005, 9
:23-27.
1700632941
1700632942
[30] Cauley JA, Black DM, Barrett-Conner E, et al. For the HERS Research Group. Effects of hormone replacement therapy on clinical fractures and height loss: The heart and estrogen/progestin replacement study. Am J Med, 2001, 110
:442-450.
1700632943
1700632944
[31] Hulley S, Furberg C, Barrett-Connor E, et al. For the HERS Research Group. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin replacement study follow-up（HERS Ⅱ). JAMA, 2002, 288
:58-66.
1700632945
1700632946
[32] Heinemann DF. Osteoporosis. An overview of the national osteoporosis foundation clinical practice guide. Geriatrics, 2000, 55
:31-36.
1700632947
1700632948
[33] Bryant HU. Mechanism of actionand preclinical profile of raloxifene: A selective estrogen receptor modulator. Rev Endocr Metab Disord. 2001, 2
:129-138.
1700632949
1700632950
[34] Ettinger B, Black DM, Mitlak BH, et al. For the multiple outcomes of raloxifene evaluation（MORE）Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999, 282
:637-645.
1700632951
1700632952
[35] Delmas PD, Ensrud KE, Adachi JD, et al. For the multiple outcomes of raloxifene evaluation investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from arandomized clinical trial. J Clin Endocrinol Metab. 2002, 87
:3609-3617.
1700632953
1700632954
[36] Kelminski A. The study of tamoxifen and raloxifene（STAR trial）for the prevention of breast cancer. Hawaii Med J, 2002, 61
:209-210.
1700632955
1700632956
[37] Brown Jp, Josse RG. For the Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. published corrections appear in CMAJ, 2003, 168
:400.
1700632957
[
上一页 ]
[ :1.700632908e+09 ]
[
下一页 ]